PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jpnSubmit a ManuscriptEmail AlertsAbout JPNJournal of Psychiatry and Neuroscience
 
J Psychiatry Neurosci. 1997 March; 22(2): 99–104.
PMCID: PMC1188831

Substance abuse and cognitive functioning in schizophrenia.

Abstract

Individuals with schizophrenia have an increased vulnerability to abuse drugs or alcohol. This vulnerability can interfere with the course and treatment of the disorder and may also have a detrimental effect on already compromised cognitive functioning. This study has a matched, cross-sectional design and compares the social and cognitive functioning and the symptoms of 33 schizophrenia subjects who abuse substances with 33 nonabusing schizophrenia subjects. Subjects were matched on sex, age, and education variables and were all outpatients. Measures of social functioning and quality of life were used. Assessment of cognitive functioning included measures of verbal ability, attention, executive functioning, and verbal and visual memory. Substance-abusing subjects had significantly lower quality of life. There were no other differences between the 2 groups. Several explanations are offered for the lack of observed differences in cognitive functioning.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1017K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Arndt S, Tyrrell G, Flaum M, Andreasen NC. Comorbidity of substance abuse and schizophrenia: the role of pre-morbid adjustment. Psychol Med. 1992 May;22(2):379–388. [PubMed]
  • Bartels SJ, Teague GB, Drake RE, Clark RE, Bush PW, Noordsy DL. Substance abuse in schizophrenia: service utilization and costs. J Nerv Ment Dis. 1993 Apr;181(4):227–232. [PubMed]
  • Birchwood M, Smith J, Cochrane R, Wetton S, Copestake S. The Social Functioning Scale. The development and validation of a new scale of social adjustment for use in family intervention programmes with schizophrenic patients. Br J Psychiatry. 1990 Dec;157:853–859. [PubMed]
  • Cleghorn JM, Kaplan RD, Szechtman B, Szechtman H, Brown GM, Franco S. Substance abuse and schizophrenia: effect on symptoms but not on neurocognitive function. J Clin Psychiatry. 1991 Jan;52(1):26–30. [PubMed]
  • Dixon L, Haas G, Weiden PJ, Sweeney J, Frances AJ. Drug abuse in schizophrenic patients: clinical correlates and reasons for use. Am J Psychiatry. 1991 Feb;148(2):224–230. [PubMed]
  • Drake RE, Osher FC, Wallach MA. Alcohol use and abuse in schizophrenia. A prospective community study. J Nerv Ment Dis. 1989 Jul;177(7):408–414. [PubMed]
  • Eckardt MJ, Stapleton JM, Rawlings RR, Davis EZ, Grodin DM. Neuropsychological functioning in detoxified alcoholics between 18 and 35 years of age. Am J Psychiatry. 1995 Jan;152(1):53–59. [PubMed]
  • el-Guebaly N, Hodgins DC. Schizophrenia and substance abuse: prevalence issues. Can J Psychiatry. 1992 Dec;37(10):704–710. [PubMed]
  • Heinrichs DW, Hanlon TE, Carpenter WT., Jr The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull. 1984;10(3):388–398. [PubMed]
  • Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–276. [PubMed]
  • Lieberman J, Jody D, Geisler S, Vital-Herne J, Alvir JM, Walsleben J, Woerner MG. Treatment outcome of first episode schizophrenia. Psychopharmacol Bull. 1989;25(1):92–96. [PubMed]
  • Mueser KT, Yarnold PR, Levinson DF, Singh H, Bellack AS, Kee K, Morrison RL, Yadalam KG. Prevalence of substance abuse in schizophrenia: demographic and clinical correlates. Schizophr Bull. 1990;16(1):31–56. [PubMed]
  • Sevy S, Kay SR, Opler LA, van Praag HM. Significance of cocaine history in schizophrenia. J Nerv Ment Dis. 1990 Oct;178(10):642–648. [PubMed]

Articles from Journal of Psychiatry & Neuroscience : JPN are provided here courtesy of Canadian Medical Association